Genprex, Inc. has revealed encouraging preclinical data for their NPRL2 gene therapy aimed at treating resistant non-small cell lung cancer (NSCLC).

The company's non-viral Oncoprex Delivery System was effective in delivering the NPRL2 tumor suppressor gene in KRAS/STK11 mutant anti-PD1 resistant NSCLC within a humanized mouse model.

NPRL2 gene therapy demonstrated anti-tumor effects in both humanized and non-humanized mouse models, including those treated with anti-PD1 drugs.

These findings enhance the credibility of the Oncoprex Delivery System and suggest a potential new drug candidate in Genprex's research pipeline.

Genprex is also advancing Reqorsa Immunogene Therapy, its lead product candidate, through clinical trials for NSCLC and small cell lung cancer (SCLC).

The promising results for NPRL2 therapy, which uses lipid-based nanoparticles for gene delivery, indicate a new possible treatment avenue for NSCLC patients who are not responding to current therapies.